- Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study
-
Gupta M, Choudhury , Rawal S, Goel HC, Rao SA
- KMID: 2431979
- Nucl Med Mol Imaging.
- 2018 Dec;52(6):420-429.
- doi: 10.1007/s13139-018-0548-3
PURPOSE: The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status
-
Gupta M, Choudhury , Rawal S, Karthikeyan G, Talwar V, Dutta KD, Singh A
- KMID: 2469586
- Nucl Med Mol Imaging.
- 2019 Dec;53(6):423-431.
- doi: 10.1007/s13139-019-00624-8
PURPOSE: The aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance... -
- CITED
-
- Close
- SHARE
-
- Close
